USA Carla Smith looks at the three vital components behind successful strategic alliances in US healthcare:disruption, data-driven demands and convenient care delivery. Throughout my career, to bring positive and lasting change to the health sector, I’ve brokered more collaborative efforts than I can count. Strategic alliances between health leaders, nonprofit…
UAE Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research…
USA Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs” in the US and the steps that need to be taken to remedy the situation. Globally, 700,000 people lose their lives to drug-resistant infections each year In November 2019,…
Opinion Monica Weldon, CEO and president of Bridge the Gap – SYNGAP Education and Research Foundation, shares her recent experience at the US Drug Law and Regulation course in Washington, DC and expands on the role that patient associations can play in the drug development process. In today’s environment of…
USA Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene therapies in the US and beyond. To keep pace with the remarkable and continuing growth of gene therapy, FDA’s…
USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications. In a nutshell: competition brings prices down across the board Biologic drugs…
USA AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward. Discussion and debate related to cost and quality in healthcare has never been more pronounced or more contentious, whether focusing on…
USA BioNJ’s president and CEO Debbie Hart reflects on the association’s mission of creating a robust and engaging life sciences ecosystem in New Jersey. Hart also outlines how BioNJ is hoping to continue to grow the region’s reputation as a hub that stands out for its level of expertise, favourable geographic…
USA Carla Smith looks at the various cybersecurity risks that exist across the US healthcare continuum and the steps that executive leadership can take to combat this threat. Keeping patient data safe and secure remains a challenge. Thanks to a 9-year review of experiences in the United States, we know…
USA The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases,” picking a number of innovative medicines that it says have seen price hikes without sufficient substantiation. While the study made the headlines, Certara’s Ulrich Neumann calls for some scepticism and…
UAE The UAE is putting a greater emphasis on healthcare than ever before as part of its ‘Vision 2021’ model. With the aim of being “flexible in adopting new economic models and capitalizing on global economic partnerships,” the Emirates are seeing greater numbers of investments and partnerships in healthcare, many of…
China The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their own firms. Dubbed ‘Sea Turtles’ (‘海龟’ haigui), as ‘海’ (hai) means ‘ocean’ in Chinese and ‘龟’ (gui) is a homonym…
See our Cookie Privacy Policy Here